ibuprofen has been researched along with Cystic Fibrosis in 72 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "High-dose ibuprofen (IBU) may slow the decline of lung function in patients with cystic fibrosis (CF), but its use has been limited due to concerns over renal and gastrointestinal toxicity." | 9.19 | High-dose ibuprofen is not associated with increased biomarkers of kidney injury in patients with cystic fibrosis. ( Diehl, S; Ferguson, M; Guillet, A; Lahiri, T, 2014) |
| "To assess the effectiveness and safety of high-dose ibuprofen when used as part of routine therapy in patients with cystic fibrosis (CF)." | 9.12 | High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. ( Cantin, AM; Corey, M; Lands, LC; Manson, D; Milner, R, 2007) |
| "Long-term treatment with ibuprofen twice daily, at doses that achieve peak plasma concentration (Cmax) >50 microg/ml, slows progression of lung disease in patients with cystic fibrosis (CF)." | 9.10 | Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. ( Davis, PB; Finney, MR; Hilliard, JB; Hilliard, KA; Hoppel, CL; Kirchner, HL; Konstan, MW; Krenicky, JE, 2003) |
| "The objectives of this study were to compare the pharmacokinetic parameters of ibuprofen administered as a suspension, chewable tablet, or tablet in children with cystic fibrosis and to determine the optimal blood sampling times for measuring ibuprofen peak concentrations." | 9.09 | The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis. ( Glasscock, BJ; Graham, KM; Kustra, RP; Retsch-Bogart, GZ; Scott, CS; Smith, PC, 1999) |
| "In patients with cystic fibrosis and mild lung disease, high-dose ibuprofen, taken consistently for four years, significantly slows the progression of the lung disease without serious adverse effects." | 9.08 | Effect of high-dose ibuprofen in patients with cystic fibrosis. ( Byard, PJ; Davis, PB; Hoppel, CL; Konstan, MW, 1995) |
| "Antiinflammatory therapy with ibuprofen has been proposed to retard the progression of lund disease in cystic fibrosis (CF)." | 9.07 | Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. ( Chai, BL; Davis, PB; Hoppel, CL; Konstan, MW, 1991) |
| "Ibuprofen was first advocated as a chronic therapy for cystic fibrosis lung disease in 1995, following a favorable report of a 4-year controlled trial." | 8.84 | Ibuprofen therapy for cystic fibrosis lung disease: revisited. ( Konstan, MW, 2008) |
| "This report demonstrates that gastrointestinal tract anatomical abnormalities or dysmotility may be contraindications for therapy with high-dose ibuprofen in patients with cystic fibrosis." | 8.82 | High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report. ( Anbar, RD; Mackey, JE, 2004) |
| " To illustrate this, the stepwise development of an integrated disease/pharmacokinetics/pharmacodynamics model of antipyretic efficacy of ibuprofen in children with cystic fibrosis (CF) is presented along with therapy optimization suggestions." | 7.96 | Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: Physiologically-based modeling as a candle in the dark. ( Cicali, B; Cristofoletti, R; Kim, S; Long, T, 2020) |
| "Clinical trials have demonstrated the benefits of ibuprofen therapy in cystic fibrosis (CF) patients, an effect that is currently attributed to ibuprofen's anti-inflammatory properties." | 7.88 | Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens. ( Cannon, CL; Chen, Q; Gordon, VD; Greenberg, DE; Le, HH; Marshall-Batty, KR; Rodesney, CA; Shah, PN; Smolen, JA; Tagaev, JA, 2018) |
| "In a propensity-score matched cohort study of children with cystic fibrosis, we observed an association between high-dose ibuprofen use and both slower lung function decline and improved long-term survival." | 7.88 | Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. ( Foreman, AJ; Konstan, MW; Morgan, WJ; Neiman, EA; Pasta, DJ; Sawicki, GS; VanDevanter, DR, 2018) |
| "High-dose ibuprofen, an effective anti-inflammatory therapy for the treatment of cystic fibrosis (CF), has been shown to preserve lung function in a pediatric population." | 7.83 | Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. ( Corey, DA; Cotton, CU; Endres, T; Kampman, CM; Kelley, TJ; Rymut, SM, 2016) |
| "High-dose ibuprofen is clinically effective in cystic fibrosis (CF); however, its molecular mechanisms are poorly understood." | 7.76 | Ibuprofen modulates NF-kB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells. ( Dauletbaev, N; Eklove, D; Iskandar, M; Lam, J; Lands, LC, 2010) |
| "To assess the effects on nasal polyposis from high-dose ibuprofen therapy used in children with cystic fibrosis (CF) pulmonary disease." | 7.74 | Ibuprofen therapy and nasal polyposis in cystic fibrosis patients. ( Conley, SF; Gershan, WM; Lindstrom, DR; Splaingard, ML, 2007) |
| "Slower rates of FEV(1) decline are seen in children and adolescents with cystic fibrosis who are treated with ibuprofen." | 7.74 | Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. ( Davis, PB; Konstan, MW; Schluchter, MD; Xue, W, 2007) |
| "Despite its apparent benefits, high-dose ibuprofen has been infrequently applied to children with cystic fibrosis." | 7.74 | Use of high-dose ibuprofen in a pediatric cystic fibrosis center. ( Boyle, M; Fennell, PB; Ferkol, T; Quante, J; Strunk, R; Wilson, K, 2007) |
| "To evaluate ibuprofen population pharmacokinetics in a large series of data collected in children with cystic fibrosis (CF) treated with high doses of ibuprofen (59 patients; 2-18 years), and to identify the main causes responsible for the considerable interindividual variability in ibuprofen serum levels." | 7.72 | Population pharmacokinetics of high dose ibuprofen in cystic fibrosis. ( Arranz, I; Escribano, A; Juste, M; Lanao, JM; Martín-Suárez, A; Mercader, J; Mora, F; Ripoll, E; Vázquez, C, 2003) |
| "High-dose ibuprofen therapy has demonstrated to slow deterioration in pulmonary function in children with cystic fibrosis with mild lung disease." | 7.71 | Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. ( Aminimanizani, A; Beringer, P; Scott, C; Synold, T, 2002) |
| "Gentamicin and standard-dose ibuprofen were administered to an adolescent with cystic fibrosis who developed renal failure and severe vestibulotoxicity." | 7.71 | Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen. ( Henry, MM; Retsch-Bogart, GZ; Scott, CS, 2001) |
| "Chiral inversion of R(-)- to S(+)-ibuprofen in children with cystic fibrosis was investigated." | 7.70 | Pharmacokinetics of ibuprofen enantiomers in children with cystic fibrosis. ( Dong, JQ; Ni, L; Retsch-Bogart, GZ; Scott, CS; Smith, PC, 2000) |
| "Limited data to date indicate that ibuprofen, when used in large doses to treat the pulmonary manifestations of cystic fibrosis, is relatively safe." | 7.70 | Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis. ( Bell, EA; Foote, JM; Grothe, R; Wellendorf, J; Zivkovich, V, 1999) |
| "To determine the pharmacokinetic disposition of high doses of ibuprofen in patients with cystic fibrosis (CF), and to evaluate the reliability of intrapatient dosage adjustments to achieve recommended peak ibuprofen plasma concentrations." | 7.70 | Pharmacokinetics of ibuprofen in patients with cystic fibrosis. ( Murry, DJ; Oermann, CM; Ou, CN; Rognerud, C; Seilheimer, DK; Sockrider, MM, 1999) |
| "High doses of ibuprofen have been shown to delay the progression of lung disease without serious adverse effects in patients with cystic fibrosis." | 7.69 | Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. ( Colin, AA; Galpchian, V; Harris, N; Law, T; Rifai, N; Sakamoto, M, 1996) |
| "Ibuprofen is a potent anti-inflammatory agent that demonstrates inhibition of neutrophil activity in vitro at concentrations between 50 and 100 mg/L, whereas lower concentrations result in an increase in inflammatory mediators." | 6.42 | Pharmacokinetics of Ibuprofen in children with cystic fibrosis. ( Beringer, PM; Gill, MA; Han, EE; Louie, SG; Shapiro, BJ, 2004) |
| "Ibuprofen was identified as a CFTR corrector." | 5.42 | Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking. ( Carlile, GW; Goepp, J; Hanrahan, JW; Kus, B; Liao, J; Macknight, SD; Matthes, E; Robert, R; Rotin, D; Thomas, DY, 2015) |
| "Ibuprofen did not increase the pulmonary burden of Pseudomonas, and the ibuprofen-treated infected animals gained weight better than placebo-treated controls." | 5.28 | Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. ( Davis, PB; Konstan, MW; Vargo, KM, 1990) |
| "High-dose ibuprofen (IBU) may slow the decline of lung function in patients with cystic fibrosis (CF), but its use has been limited due to concerns over renal and gastrointestinal toxicity." | 5.19 | High-dose ibuprofen is not associated with increased biomarkers of kidney injury in patients with cystic fibrosis. ( Diehl, S; Ferguson, M; Guillet, A; Lahiri, T, 2014) |
| "To assess the effectiveness and safety of high-dose ibuprofen when used as part of routine therapy in patients with cystic fibrosis (CF)." | 5.12 | High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. ( Cantin, AM; Corey, M; Lands, LC; Manson, D; Milner, R, 2007) |
| "Long-term treatment with ibuprofen twice daily, at doses that achieve peak plasma concentration (Cmax) >50 microg/ml, slows progression of lung disease in patients with cystic fibrosis (CF)." | 5.10 | Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. ( Davis, PB; Finney, MR; Hilliard, JB; Hilliard, KA; Hoppel, CL; Kirchner, HL; Konstan, MW; Krenicky, JE, 2003) |
| "The objectives of this study were to compare the pharmacokinetic parameters of ibuprofen administered as a suspension, chewable tablet, or tablet in children with cystic fibrosis and to determine the optimal blood sampling times for measuring ibuprofen peak concentrations." | 5.09 | The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis. ( Glasscock, BJ; Graham, KM; Kustra, RP; Retsch-Bogart, GZ; Scott, CS; Smith, PC, 1999) |
| "In patients with cystic fibrosis and mild lung disease, high-dose ibuprofen, taken consistently for four years, significantly slows the progression of the lung disease without serious adverse effects." | 5.08 | Effect of high-dose ibuprofen in patients with cystic fibrosis. ( Byard, PJ; Davis, PB; Hoppel, CL; Konstan, MW, 1995) |
| "Antiinflammatory therapy with ibuprofen has been proposed to retard the progression of lund disease in cystic fibrosis (CF)." | 5.07 | Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. ( Chai, BL; Davis, PB; Hoppel, CL; Konstan, MW, 1991) |
| "High-dose ibuprofen can slow the progression of lung disease in people with cystic fibrosis, especially in children, which suggests that strategies to modulate lung inflammation can be beneficial for people with cystic fibrosis." | 5.01 | Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. ( Lands, LC; Stanojevic, S, 2019) |
| "High-dose ibuprofen can slow the progression of lung disease in people with cystic fibrosis, especially in children, which suggests that strategies to modulate lung inflammation can be beneficial for people with cystic fibrosis." | 4.93 | Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. ( Lands, LC; Stanojevic, S, 2016) |
| "Ibuprofen was first advocated as a chronic therapy for cystic fibrosis lung disease in 1995, following a favorable report of a 4-year controlled trial." | 4.84 | Ibuprofen therapy for cystic fibrosis lung disease: revisited. ( Konstan, MW, 2008) |
| "This report demonstrates that gastrointestinal tract anatomical abnormalities or dysmotility may be contraindications for therapy with high-dose ibuprofen in patients with cystic fibrosis." | 4.82 | High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report. ( Anbar, RD; Mackey, JE, 2004) |
| " To illustrate this, the stepwise development of an integrated disease/pharmacokinetics/pharmacodynamics model of antipyretic efficacy of ibuprofen in children with cystic fibrosis (CF) is presented along with therapy optimization suggestions." | 3.96 | Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: Physiologically-based modeling as a candle in the dark. ( Cicali, B; Cristofoletti, R; Kim, S; Long, T, 2020) |
| "The use of high-dose ibuprofen as an anti-inflammatory therapy in cystic fibrosis (CF) has been shown to be an effective intervention although use is limited due to potential adverse events." | 3.91 | Acetyl-CoA carboxylase inhibition regulates microtubule dynamics and intracellular transport in cystic fibrosis epithelial cells. ( Corey, DA; Cotton, CU; Kelley, TJ; Lamb, K; Lu, B; Perez, A; Rymut, SM, 2019) |
| "Clinical trials have demonstrated the benefits of ibuprofen therapy in cystic fibrosis (CF) patients, an effect that is currently attributed to ibuprofen's anti-inflammatory properties." | 3.88 | Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens. ( Cannon, CL; Chen, Q; Gordon, VD; Greenberg, DE; Le, HH; Marshall-Batty, KR; Rodesney, CA; Shah, PN; Smolen, JA; Tagaev, JA, 2018) |
| "In a propensity-score matched cohort study of children with cystic fibrosis, we observed an association between high-dose ibuprofen use and both slower lung function decline and improved long-term survival." | 3.88 | Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. ( Foreman, AJ; Konstan, MW; Morgan, WJ; Neiman, EA; Pasta, DJ; Sawicki, GS; VanDevanter, DR, 2018) |
| "High-dose ibuprofen, an effective anti-inflammatory therapy for the treatment of cystic fibrosis (CF), has been shown to preserve lung function in a pediatric population." | 3.83 | Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. ( Corey, DA; Cotton, CU; Endres, T; Kampman, CM; Kelley, TJ; Rymut, SM, 2016) |
| "Here, the preparation of mucus-penetrating nanoparticles for pulmonary administration of ibuprofen in patients with cystic fibrosis is described." | 3.83 | Pegylated Polyaspartamide-Polylactide-Based Nanoparticles Penetrating Cystic Fibrosis Artificial Mucus. ( Cavallaro, G; Craparo, EF; Giammona, G; Porsio, B; Sardo, C, 2016) |
| "High-dose ibuprofen is clinically effective in cystic fibrosis (CF); however, its molecular mechanisms are poorly understood." | 3.76 | Ibuprofen modulates NF-kB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells. ( Dauletbaev, N; Eklove, D; Iskandar, M; Lam, J; Lands, LC, 2010) |
| "Despite its apparent benefits, high-dose ibuprofen has been infrequently applied to children with cystic fibrosis." | 3.74 | Use of high-dose ibuprofen in a pediatric cystic fibrosis center. ( Boyle, M; Fennell, PB; Ferkol, T; Quante, J; Strunk, R; Wilson, K, 2007) |
| "Slower rates of FEV(1) decline are seen in children and adolescents with cystic fibrosis who are treated with ibuprofen." | 3.74 | Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. ( Davis, PB; Konstan, MW; Schluchter, MD; Xue, W, 2007) |
| "To assess the effects on nasal polyposis from high-dose ibuprofen therapy used in children with cystic fibrosis (CF) pulmonary disease." | 3.74 | Ibuprofen therapy and nasal polyposis in cystic fibrosis patients. ( Conley, SF; Gershan, WM; Lindstrom, DR; Splaingard, ML, 2007) |
| "Small-scale clinical trials show that treatment of cystic fibrosis (CF) patients with ibuprofen, a nonsteroidal anti-inflammatory drug, improves the symptoms of CF and slows down the decline of lung function." | 3.74 | Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR. ( Hu, J; Li, J; Lu, WY; Macdonald, JF; Tsui, LC; Xiang, YY; Ye, L, 2008) |
| "To evaluate ibuprofen population pharmacokinetics in a large series of data collected in children with cystic fibrosis (CF) treated with high doses of ibuprofen (59 patients; 2-18 years), and to identify the main causes responsible for the considerable interindividual variability in ibuprofen serum levels." | 3.72 | Population pharmacokinetics of high dose ibuprofen in cystic fibrosis. ( Arranz, I; Escribano, A; Juste, M; Lanao, JM; Martín-Suárez, A; Mercader, J; Mora, F; Ripoll, E; Vázquez, C, 2003) |
| "Gentamicin and standard-dose ibuprofen were administered to an adolescent with cystic fibrosis who developed renal failure and severe vestibulotoxicity." | 3.71 | Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen. ( Henry, MM; Retsch-Bogart, GZ; Scott, CS, 2001) |
| "High-dose ibuprofen therapy has demonstrated to slow deterioration in pulmonary function in children with cystic fibrosis with mild lung disease." | 3.71 | Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. ( Aminimanizani, A; Beringer, P; Scott, C; Synold, T, 2002) |
| "Limited data to date indicate that ibuprofen, when used in large doses to treat the pulmonary manifestations of cystic fibrosis, is relatively safe." | 3.70 | Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis. ( Bell, EA; Foote, JM; Grothe, R; Wellendorf, J; Zivkovich, V, 1999) |
| "Chiral inversion of R(-)- to S(+)-ibuprofen in children with cystic fibrosis was investigated." | 3.70 | Pharmacokinetics of ibuprofen enantiomers in children with cystic fibrosis. ( Dong, JQ; Ni, L; Retsch-Bogart, GZ; Scott, CS; Smith, PC, 2000) |
| "To determine the pharmacokinetic disposition of high doses of ibuprofen in patients with cystic fibrosis (CF), and to evaluate the reliability of intrapatient dosage adjustments to achieve recommended peak ibuprofen plasma concentrations." | 3.70 | Pharmacokinetics of ibuprofen in patients with cystic fibrosis. ( Murry, DJ; Oermann, CM; Ou, CN; Rognerud, C; Seilheimer, DK; Sockrider, MM, 1999) |
| "High doses of ibuprofen have been shown to delay the progression of lung disease without serious adverse effects in patients with cystic fibrosis." | 3.69 | Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. ( Colin, AA; Galpchian, V; Harris, N; Law, T; Rifai, N; Sakamoto, M, 1996) |
| " In one trial, long-term use of high-dose ibuprofen was associated with reduced intravenous antibiotic usage, improved nutritional and radiological pulmonary status." | 2.49 | Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. ( Lands, LC; Stanojevic, S, 2013) |
| "Ibuprofen is a potent anti-inflammatory agent that demonstrates inhibition of neutrophil activity in vitro at concentrations between 50 and 100 mg/L, whereas lower concentrations result in an increase in inflammatory mediators." | 2.42 | Pharmacokinetics of Ibuprofen in children with cystic fibrosis. ( Beringer, PM; Gill, MA; Han, EE; Louie, SG; Shapiro, BJ, 2004) |
| "Airway inflammation is now recognized as a major factor in the pathogenesis of lung disease in cystic fibrosis." | 2.42 | [Airway inflammation in cystic fibrosis]. ( Derelle, J, 2003) |
| "Airway inflammation is now recognized as a major factor in the pathogenesis of cystic fibrosis (CF) lung disease." | 2.39 | Treatment of airway inflammation in cystic fibrosis. ( Konstan, MW, 1996) |
| "Xylitol was chosen as a hydrophilizer for the final prodrug, enhancing the water solubility of ibuprofen." | 1.72 | Xylitol as a Hydrophilization Moiety for a Biocatalytically Synthesized Ibuprofen Prodrug. ( Costa, S; Cristofori, V; Lampronti, I; Summa, D; Tamburini, E; Trapella, C; Tupini, C; Zappaterra, F, 2022) |
| "Ibuprofen was identified as a CFTR corrector." | 1.42 | Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking. ( Carlile, GW; Goepp, J; Hanrahan, JW; Kus, B; Liao, J; Macknight, SD; Matthes, E; Robert, R; Rotin, D; Thomas, DY, 2015) |
| "Ursodiol, the drug of choice for the treatment of cystic fibrosis liver disease, may offer a safe method of using high-dose IBU in these patients by ameliorating the enteropathy." | 1.31 | Ursodeoxycholic acid ameliorates ibuprofen-induced enteropathy in the rat. ( Beno, DW; Jiyamapa-Serna, VA; Kimura, RE; Lloyd-Still, JD; Uhing, MR, 2001) |
| " Long-term use of oral corticosteroids (OCS) and ibuprofen (IBU) has been proven efficacious in slowing the progression of CF." | 1.30 | The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. ( Konstan, MW; Oermann, CM; Sockrider, MM, 1999) |
| "Ibuprofen did not increase the pulmonary burden of Pseudomonas, and the ibuprofen-treated infected animals gained weight better than placebo-treated controls." | 1.28 | Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. ( Davis, PB; Konstan, MW; Vargo, KM, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 21 (29.17) | 18.2507 |
| 2000's | 27 (37.50) | 29.6817 |
| 2010's | 19 (26.39) | 24.3611 |
| 2020's | 5 (6.94) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, WJ | 1 |
| Goeckeler-Fried, JL | 1 |
| Havasi, V | 1 |
| Chiang, A | 1 |
| Rowe, SM | 1 |
| Plyler, ZE | 1 |
| Hong, JS | 1 |
| Mazur, M | 1 |
| Piazza, GA | 1 |
| Keeton, AB | 1 |
| White, EL | 1 |
| Rasmussen, L | 1 |
| Weissman, AM | 1 |
| Denny, RA | 1 |
| Brodsky, JL | 1 |
| Sorscher, EJ | 1 |
| Zappaterra, F | 1 |
| Tupini, C | 1 |
| Summa, D | 1 |
| Cristofori, V | 1 |
| Costa, S | 1 |
| Trapella, C | 1 |
| Lampronti, I | 1 |
| Tamburini, E | 1 |
| Babaei, N | 1 |
| Rasti, B | 1 |
| Zamani, H | 1 |
| Lands, LC | 6 |
| Stanojevic, S | 3 |
| Cicali, B | 1 |
| Long, T | 1 |
| Kim, S | 1 |
| Cristofoletti, R | 1 |
| Sheikh, Z | 2 |
| Bradbury, P | 2 |
| Pozzoli, M | 2 |
| Young, PM | 2 |
| Ong, HX | 2 |
| Traini, D | 2 |
| Reekie, TA | 1 |
| Robinson, PD | 1 |
| Kassiou, M | 1 |
| Shah, PN | 1 |
| Marshall-Batty, KR | 1 |
| Smolen, JA | 1 |
| Tagaev, JA | 1 |
| Chen, Q | 1 |
| Rodesney, CA | 1 |
| Le, HH | 1 |
| Gordon, VD | 1 |
| Greenberg, DE | 1 |
| Cannon, CL | 1 |
| Konstan, MW | 17 |
| VanDevanter, DR | 2 |
| Sawicki, GS | 1 |
| Pasta, DJ | 2 |
| Foreman, AJ | 1 |
| Neiman, EA | 1 |
| Morgan, WJ | 2 |
| West, NE | 1 |
| Goss, CH | 1 |
| Nichols, DP | 2 |
| Bruch, BA | 1 |
| Singh, SB | 1 |
| Ramsey, LJ | 1 |
| Starner, TD | 1 |
| Phan, H | 1 |
| Rymut, SM | 2 |
| Lu, B | 1 |
| Perez, A | 1 |
| Corey, DA | 2 |
| Lamb, K | 1 |
| Cotton, CU | 2 |
| Kelley, TJ | 2 |
| Lahiri, T | 1 |
| Guillet, A | 1 |
| Diehl, S | 1 |
| Ferguson, M | 1 |
| Chmiel, JF | 4 |
| Elborn, JS | 1 |
| Carlile, GW | 1 |
| Robert, R | 1 |
| Goepp, J | 1 |
| Matthes, E | 1 |
| Liao, J | 1 |
| Kus, B | 1 |
| Macknight, SD | 1 |
| Rotin, D | 1 |
| Hanrahan, JW | 1 |
| Thomas, DY | 1 |
| Accurso, FJ | 1 |
| Lymp, J | 1 |
| Mayer-Hamblett, N | 1 |
| Rose, LM | 1 |
| Ramsey, BW | 1 |
| Craparo, EF | 1 |
| Porsio, B | 1 |
| Sardo, C | 1 |
| Giammona, G | 1 |
| Cavallaro, G | 1 |
| Kampman, CM | 1 |
| Endres, T | 1 |
| Ren, CL | 1 |
| Rasouliyan, L | 1 |
| Wagener, JS | 1 |
| Dauletbaev, N | 1 |
| Lam, J | 1 |
| Eklove, D | 1 |
| Iskandar, M | 1 |
| Kieninger, E | 1 |
| Regamey, N | 1 |
| Selbst, SM | 1 |
| Osterhoudt, K | 1 |
| Davis, PB | 7 |
| Salcedo Posadas, A | 1 |
| Girón Moreno, R | 1 |
| Beltrán Bengoechea, B | 1 |
| Derelle, J | 1 |
| Krenicky, JE | 1 |
| Finney, MR | 1 |
| Kirchner, HL | 1 |
| Hilliard, KA | 1 |
| Hilliard, JB | 1 |
| Hoppel, CL | 3 |
| Arranz, I | 1 |
| Martín-Suárez, A | 1 |
| Lanao, JM | 1 |
| Mora, F | 1 |
| Vázquez, C | 1 |
| Escribano, A | 1 |
| Juste, M | 1 |
| Mercader, J | 1 |
| Ripoll, E | 1 |
| Han, EE | 1 |
| Beringer, PM | 1 |
| Louie, SG | 1 |
| Gill, MA | 1 |
| Shapiro, BJ | 1 |
| Mackey, JE | 1 |
| Anbar, RD | 1 |
| O'Sullivan, BP | 1 |
| Linden, MD | 1 |
| Frelinger, AL | 1 |
| Barnard, MR | 1 |
| Spencer-Manzon, M | 1 |
| Morris, JE | 1 |
| Salem, RO | 1 |
| Laposata, M | 1 |
| Michelson, AD | 1 |
| Dinwiddie, R | 1 |
| Fennell, PB | 1 |
| Quante, J | 1 |
| Wilson, K | 1 |
| Boyle, M | 1 |
| Strunk, R | 1 |
| Ferkol, T | 1 |
| Vij, N | 1 |
| Amoako, MO | 1 |
| Mazur, S | 1 |
| Zeitlin, PL | 1 |
| Bush, A | 1 |
| Davies, J | 1 |
| Milner, R | 1 |
| Cantin, AM | 1 |
| Manson, D | 1 |
| Corey, M | 1 |
| Schluchter, MD | 1 |
| Xue, W | 1 |
| Lindstrom, DR | 1 |
| Conley, SF | 1 |
| Splaingard, ML | 1 |
| Gershan, WM | 1 |
| Li, J | 1 |
| Xiang, YY | 1 |
| Ye, L | 1 |
| Tsui, LC | 1 |
| Macdonald, JF | 1 |
| Hu, J | 1 |
| Lu, WY | 1 |
| Byard, PJ | 2 |
| Carter, ER | 1 |
| Moffitt, DR | 1 |
| Colp, C | 1 |
| Lieberman, J | 1 |
| Colten, HR | 1 |
| Rifai, N | 1 |
| Sakamoto, M | 1 |
| Law, T | 1 |
| Galpchian, V | 1 |
| Harris, N | 1 |
| Colin, AA | 1 |
| Miele, L | 1 |
| Cordella-Miele, E | 1 |
| Xing, M | 1 |
| Frizzell, R | 1 |
| Mukherjee, AB | 1 |
| Way, BA | 1 |
| Wilhite, TR | 1 |
| Smith, CH | 1 |
| Landt, M | 1 |
| Kovesi, TA | 1 |
| Swartz, R | 1 |
| MacDonald, N | 1 |
| Voter, KZ | 1 |
| Scott, CS | 3 |
| Retsch-Bogart, GZ | 3 |
| Kustra, RP | 1 |
| Graham, KM | 1 |
| Glasscock, BJ | 1 |
| Smith, PC | 2 |
| Oermann, CM | 3 |
| Sockrider, MM | 2 |
| Murry, DJ | 1 |
| Ou, CN | 1 |
| Rognerud, C | 1 |
| Seilheimer, DK | 1 |
| Bell, EA | 1 |
| Grothe, R | 1 |
| Zivkovich, V | 1 |
| Foote, JM | 1 |
| Wellendorf, J | 1 |
| Balfour-Lynn, IM | 1 |
| Dezateux, C | 1 |
| Saleh, A | 1 |
| Figarella, C | 1 |
| Kammouni, W | 1 |
| Marchand-Pinatel, S | 1 |
| Lazdunski, A | 1 |
| Tubul, A | 1 |
| Brun, P | 1 |
| Merten, MD | 1 |
| Dong, JQ | 1 |
| Ni, L | 1 |
| Ciabattoni, G | 1 |
| Davì, G | 1 |
| Collura, M | 1 |
| Iapichino, L | 1 |
| Pardo, F | 1 |
| Ganci, A | 1 |
| Romagnoli, R | 1 |
| Maclouf, J | 1 |
| Patrono, C | 1 |
| Henry, MM | 1 |
| Lloyd-Still, JD | 1 |
| Beno, DW | 1 |
| Uhing, MR | 1 |
| Jiyamapa-Serna, VA | 1 |
| Kimura, RE | 1 |
| Beringer, P | 1 |
| Aminimanizani, A | 1 |
| Synold, T | 1 |
| Scott, C | 1 |
| Thompson, AB | 1 |
| Smits, WL | 1 |
| Fick, RB | 1 |
| Chai, BL | 1 |
| Vargo, KM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of IL-17 Neutrophils in CF Lung Inflammation[NCT02025829] | 14 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| Evaluation of the Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation, Measures of Oxidative Stress, and Neutrophil Migration to Mucosal Surfaces in Healthy and CF Subjects[NCT01315665] | 15 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults[NCT02060006] | Phase 3 | 200 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Phase II Study: LYM-X-SORB™, an Organized Lipid Matrix: Fatty Acids and Choline in CF[NCT00406536] | Phase 2 | 110 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
In the Exacerbation/IV Antibiotics Cohort--Subjects will serve as their own controls. The percentage of neutrophils (in sputum) positive for IL-17 was determined by flow cytometry for each subject at the beginning and end of treatment for a pulmonary exacerbation. Sputum IL-17 neutrophil counts will be compared to the change in lung function (FEV1) as determined by spirometry (American Thoracic Society standards). (NCT02025829)
Timeframe: End of Treatment, two weeks. Samples will be obtained from each study volunteer at the beginning of IV antibiotic treatment and at the completion of antibiotic treatment for a pulmonary exacerbation
| Intervention | % of neutrophils positive for IL-17 (Mean) |
|---|---|
| Begining of Exacerbation | 55 |
| End of Exacerbation | 4 |
In the Exacerbation/IV Antibiotics Cohort--Measurement of sputum inflammatory mediators by multiplex assay for IL-1β, IL-6, IL-8, and IL-17A. Neutrophil elastase determined by colorimetric assay. Measurements at the beginning of IV antibiotic treatment and after 2 weeks antibiotic treatment for a pulmonary exacerbation (NCT02025829)
Timeframe: End of Treatment, two weeks. Samples will be obtained from each study volunteer at the beginning of IV antibiotic treatment and at the completion of antibiotic treatment for a pulmonary exacerbation
| Intervention | pg/ml (Mean) | ||||
|---|---|---|---|---|---|
| IL-1b (pg/ml) | IL-6 (pg/ml) | IL-8 (pg/ml) | IL-17 (pg/ml) | Neutrophil elastase activity (pg/ml) | |
| Begining of Exacerbation | 2313 | 53 | 5785 | 302 | 195 |
| End of Exacerbation | 757 | 37 | 3428 | 147 | 53 |
Change in gingival neutrophils measured after 5 days of study treatment (consuming broccoli sprouts). Patients will perform mouthwashes with normal saline. Neutrophil counts will be performed on fresh samples. Acridine orange will be added to the saline rinses and neutrophils will be counted under the microscope. (NCT01315665)
Timeframe: Baseline and end of 5 day treatment period
| Intervention | Neutrophils/mL (Log10) (Mean) |
|---|---|
| Healthy Volunteers | -0.06 |
| Subjects With Cystic Fibrosis | -0.02 |
Change in lymphocyte glutathione measurements after 5 days of study treatment (consuming broccoli sprouts). (NCT01315665)
Timeframe: Baseline and end of 5 day treatment period
| Intervention | Micro Molar (Mean) |
|---|---|
| Healthy Volunteers | 14.3 |
| Subjects With Cystic Fibrosis | 4.7 |
Change in urine bromotyrosine (measured by mass spectrometry) will be measured after 5 days of study treatment (consuming broccoli sprouts). (NCT01315665)
Timeframe: Baseline and end of 5 day treatment period
| Intervention | ng/mg creatinine (Log10) (Mean) |
|---|---|
| Healthy Volunteers | 0.09 |
| Subjects With Cystic Fibrosis | 0.01 |
Number of subjects with activated Nrf-2 in the cytoplasm of nasal epithelial cells after 5 days of study treatment (consuming broccoli sprouts) (NCT01315665)
Timeframe: Baseline and of end of 5 day treatment period
| Intervention | participants (Number) | |
|---|---|---|
| Baseline | Day 5, End of treatment | |
| Healthy Volunteers | 0 | 4 |
| Subjects With Cystic Fibrosis | 0 | 4 |
18 reviews available for ibuprofen and Cystic Fibrosis
| Article | Year |
|---|---|
Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibr | 2019 |
Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Clarithromycin; Cystic Fibrosis; Huma | 2013 |
Antibiotic and anti-inflammatory therapies for cystic fibrosis.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibiotic Prophylaxis; An | 2013 |
Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroi | 2016 |
Anti-inflammatory therapies for cystic fibrosis-related lung disease.
Topics: Adrenal Cortex Hormones; Airway Obstruction; Anti-Inflammatory Agents; Clinical Trials as Topic; Cys | 2008 |
Ibuprofen therapy for cystic fibrosis lung disease: revisited.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Cystic Fibrosis; Disea | 2008 |
Ibuprofen therapy for cystic fibrosis lung disease: revisited.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Cystic Fibrosis; Disea | 2008 |
Ibuprofen therapy for cystic fibrosis lung disease: revisited.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Cystic Fibrosis; Disea | 2008 |
Ibuprofen therapy for cystic fibrosis lung disease: revisited.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Cystic Fibrosis; Disea | 2008 |
Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis.
Topics: Aerosols; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antioxidants; Cystic Fibrosis; C | 2002 |
[Complementary therapies in cystic fibrosis: evidence of therapeutic benefits and treatment recommendations].
Topics: Azithromycin; Bronchodilator Agents; Child; Complementary Therapies; Cystic Fibrosis; Deoxyribonucle | 2003 |
[Airway inflammation in cystic fibrosis].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Cystic Fibrosis; Humans; Ibuprofen | 2003 |
Pharmacokinetics of Ibuprofen in children with cystic fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Drug Interactions; Drug Monitoring; | 2004 |
High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Combined Modality Therapy; C | 2004 |
Anti-inflammatory therapy in cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Anti-Bacterial Agents; An | 2005 |
Inflammation and anti-inflammatory therapies for cystic fibrosis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antioxidants; Cystic Fibrosis; Cytokines; Disease | 2007 |
Inflammation and anti-inflammatory therapies for cystic fibrosis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antioxidants; Cystic Fibrosis; Cytokines; Disease | 2007 |
Inflammation and anti-inflammatory therapies for cystic fibrosis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antioxidants; Cystic Fibrosis; Cytokines; Disease | 2007 |
Inflammation and anti-inflammatory therapies for cystic fibrosis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antioxidants; Cystic Fibrosis; Cytokines; Disease | 2007 |
Treatment of airway inflammation in cystic fibrosis.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents; Anti-Inf | 1996 |
Adjunctive therapy in cystic firbrosis (CF).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cystic Fibrosis; Deoxyribonuclease I; Expectorants; Humans; | 1998 |
Therapies aimed at airway inflammation in cystic fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cystic Fibrosis; Glucocorticoids; Humans; Ibuprofen; In Vit | 1998 |
Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future.
Topics: alpha 1-Antitrypsin; Androstadienes; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammat | 2001 |
Immunomodulatory therapies for cystic fibrosis.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Expectorants; Humans; Ibuprofen; Immunotherapy; Interferon-g | 1992 |
8 trials available for ibuprofen and Cystic Fibrosis
| Article | Year |
|---|---|
High-dose ibuprofen is not associated with increased biomarkers of kidney injury in patients with cystic fibrosis.
Topics: Acute Kidney Injury; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Child; | 2014 |
Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Clinical Trials as Topic; Cystic Fibrosis; Fema | 2015 |
Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Cell Movement; Cystic Fibrosis; Humans; I | 2003 |
High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Canada; Child; Chromatography, High Pressure Li | 2007 |
Effect of high-dose ibuprofen in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Female; Forced Exp | 1995 |
Effect of high-dose ibuprofen in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Female; Forced Exp | 1995 |
Effect of high-dose ibuprofen in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Female; Forced Exp | 1995 |
Effect of high-dose ibuprofen in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Female; Forced Exp | 1995 |
Identifying treatments that halt progression of pulmonary disease in cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Disease Progression; Humans; Ibuprofen; | 1997 |
The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis.
Topics: Administration, Oral; Adolescent; Analysis of Variance; Area Under Curve; Child; Child, Preschool; C | 1999 |
Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects.
Topics: Child; Cystic Fibrosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibupr | 1991 |
46 other studies available for ibuprofen and Cystic Fibrosis
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu | 2016 |
Xylitol as a Hydrophilization Moiety for a Biocatalytically Synthesized Ibuprofen Prodrug.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Biocatalysis; Biological Availability; Cell Lin | 2022 |
Does ibuprofen affect the expression of alginate genes in pathogenic Pseudomonas aeruginosa strains?
Topics: Alginates; Anti-Bacterial Agents; Biofilms; Cystic Fibrosis; Humans; Ibuprofen; Pseudomonas aerugino | 2022 |
Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: Physiologically-based modeling as a candle in the dark.
Topics: Antipyretics; Child; Computer Simulation; Cystic Fibrosis; Humans; Ibuprofen; Models, Biological | 2020 |
An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biological Transport; Cell Line; Cell Li | 2020 |
Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cell Survival; Colistin; | 2021 |
Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens.
Topics: Animals; Biofilms; Bronchoalveolar Lavage Fluid; Burkholderia; Cystic Fibrosis; Gram-Negative Bacter | 2018 |
Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Dose-Response Relations | 2018 |
The Long and the Short of It in Cystic Fibrosis Clinical Research Outcomes.
Topics: Child; Cystic Fibrosis; Humans; Ibuprofen; Respiratory Physiological Phenomena | 2018 |
Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Tra | 2018 |
Treatment complexity in cystic fibrosis (CF): An increasing multifaceted challenge.
Topics: Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Ibuprofen | 2018 |
Acetyl-CoA carboxylase inhibition regulates microtubule dynamics and intracellular transport in cystic fibrosis epithelial cells.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Cell Line; | 2019 |
Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking.
Topics: Animals; Cell Movement; Cells, Cultured; Cyclooxygenase Inhibitors; Cystic Fibrosis; Cystic Fibrosis | 2015 |
Pegylated Polyaspartamide-Polylactide-Based Nanoparticles Penetrating Cystic Fibrosis Artificial Mucus.
Topics: Cell Line; Cystic Fibrosis; Humans; Ibuprofen; Mucus; Nanoparticles; Peptides; Polyesters; Polyethyl | 2016 |
Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells.
Topics: Acetylation; Adenylate Kinase; Cell Line; Cyclooxygenase Inhibitors; Cystic Fibrosis; Drug Evaluatio | 2016 |
Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Stero | 2008 |
Ibuprofen modulates NF-kB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cystic Fibrosis; Epithelial Cells; Humans; Ibupr | 2010 |
Targeting inflammation in cystic fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cystic Fibrosis; Humans; Ibuprofen; Interleukin-8; NF-kappa | 2010 |
Pediatric emergency medicine: legal briefs.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Adult; Aortic Aneurysm; Aortic Dissection; Appendicitis; | 2012 |
Population pharmacokinetics of high dose ibuprofen in cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biological Availab | 2003 |
Platelet activation in cystic fibrosis.
Topics: Adenylyl Cyclases; Adolescent; Adult; Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Arachido | 2005 |
Use of high-dose ibuprofen in a pediatric cystic fibrosis center.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Cystic Fibrosis; Femal | 2007 |
CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells.
Topics: Base Sequence; Blotting, Western; Bronchi; Cell Line; Chromatin Immunoprecipitation; Cyclic AMP; Cyc | 2008 |
Non! to non-steroidal anti-inflammatory therapy for inflammatory lung disease in cystic fibrosis (at least at the moment).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Humans; Ibuprofen; Prednisone | 2007 |
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Female; Forced Expirato | 2007 |
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Female; Forced Expirato | 2007 |
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Female; Forced Expirato | 2007 |
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Female; Forced Expirato | 2007 |
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Female; Forced Expirato | 2007 |
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Female; Forced Expirato | 2007 |
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Female; Forced Expirato | 2007 |
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Female; Forced Expirato | 2007 |
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Female; Forced Expirato | 2007 |
Ibuprofen therapy and nasal polyposis in cystic fibrosis patients.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Cohort Studies; | 2007 |
Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Tra | 2008 |
Ibuprofen in patients with cystic fibrosis.
Topics: Child; Cystic Fibrosis; Humans; Ibuprofen; Kidney Diseases | 1995 |
Ibuprofen in patients with cystic fibrosis.
Topics: Bone Development; Cystic Fibrosis; Forced Expiratory Volume; Humans; Ibuprofen; Treatment Outcome | 1995 |
Airway inflammation in cystic fibrosis.
Topics: Adult; Child, Preschool; Cystic Fibrosis; Disease Progression; Humans; Ibuprofen; Pneumonia | 1995 |
Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cystic Fibrosis; D | 1996 |
Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Calcimycin; Calcium; Cells, Cultured; Chl | 1997 |
Measurement of plasma ibuprofen by gas chromatography-mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Cystic Fibrosis; Drug Monitoring; Fenoprofen; Gas Chromatograp | 1997 |
Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.
Topics: Adolescent; Aminoglycosides; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Child; | 1998 |
The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes.
Topics: Administration, Inhalation; Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents | 1999 |
The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes.
Topics: Administration, Inhalation; Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents | 1999 |
The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes.
Topics: Administration, Inhalation; Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents | 1999 |
The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes.
Topics: Administration, Inhalation; Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents | 1999 |
Pharmacokinetics of ibuprofen in patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Child; Child, Preschool; | 1999 |
Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Catheterization; Child; Cystic Fibrosis; Female; Humans; Ib | 1999 |
Corticosteroids and ibuprofen in cystic fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Cystic Fibrosis; Glucocorticoids; Humans; Ibuprofen; | 1999 |
Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone inhibits expression of P2Y receptors in cystic fibrosis tracheal gland cells.
Topics: 4-Butyrolactone; Cell Line; Cystic Fibrosis; Homoserine; Humans; Ibuprofen; Pseudomonas aeruginosa; | 1999 |
Ibuprofen therapy in cystic fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cystic Fibrosis; Humans; Ibuprofen; Solutions; Tablets | 2000 |
Pharmacokinetics of ibuprofen enantiomers in children with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Child; Child, Preschoo | 2000 |
In vivo lipid peroxidation and platelet activation in cystic fibrosis.
Topics: Adolescent; Adult; Child; Cyclooxygenase Inhibitors; Cystic Fibrosis; Dinoprost; F2-Isoprostanes; Fe | 2000 |
Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cystic Fibrosis; Gentami | 2001 |
Ursodeoxycholic acid ameliorates ibuprofen-induced enteropathy in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Catheterization; Cholagogues and Choleretics; Cyst | 2001 |
Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Child; Child, Preschoo | 2002 |
Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis.
Topics: Animals; Body Weight; Chronic Disease; Cystic Fibrosis; Dinoprostone; Humans; Ibuprofen; Leukotriene | 1990 |